Frank Worden, MD

Articles by Frank Worden, MD

Treating BRAF V600 and NTRK Gene Fusion Positivity

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

The Future of RAI-Refractory DTC Management

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 11th 2021

Rationale for Sequencing in Second Line

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

February 4th 2021

Advice for Managing RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

Molecular Testing in Treatment Selection

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 28th 2021

Sorafenib and Lenvatinib Side Effect Profile and Dosing

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 21st 2021

Multidisciplinary Management for the Treatment of DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Approaching Treatment of Low-Volume DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Understanding Sequencing and What to Look for in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 18th 2021

Roles and Communication in Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

Management of DTC in Clinical Practice

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 11th 2021

Discussing Iodine-Refractory DTC With Patients

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

Clinical Scenarios to Consider for RAI-Refractory DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

January 4th 2021

Thyrotropin Suppression as DTC Treatment Option

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

Role of Radioiodine Treatment in DTC

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 21st 2020

DTC: Histological Subtypes and Tumor Differentiation

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

Differentiated Thyroid Cancer: Increasing Incidence

ByLori J. Wirth, MD, Massachusetts General Hospital,Jennifer Sipos, MD, Ohio State University,Frank Worden, MD

December 14th 2020

Latest Updated Articles

Understanding Sequencing and What to Look for in DTC
January 18th 2021
$RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT$
RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT
January 21st 2021
Treating BRAF V600 and NTRK Gene Fusion Positivity
February 11th 2021
$Advice for Managing RAI-Refractory DTC$
Advice for Managing RAI-Refractory DTC
January 28th 2021
Thyrotropin Suppression as DTC Treatment Option
December 21st 2020
Sorafenib and Lenvatinib Side Effect Profile and Dosing
January 21st 2021

Frank Worden, MD

Articles by Frank Worden, MD

Treating BRAF V600 and NTRK Gene Fusion Positivity

The Future of RAI-Refractory DTC Management

Rationale for Sequencing in Second Line

LIBRETTO-001 Phase 1/2 Trial Overview

Advice for Managing RAI-Refractory DTC

Molecular Testing in Treatment Selection

Sorafenib and Lenvatinib Side Effect Profile and Dosing

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

Multidisciplinary Management for the Treatment of DTC

Approaching Treatment of Low-Volume DTC

Understanding Sequencing and What to Look for in DTC

Roles and Communication in Treatment in DTC

Management of DTC in Clinical Practice

Discussing Iodine-Refractory DTC With Patients

Clinical Scenarios to Consider for RAI-Refractory DTC

Thyrotropin Suppression as DTC Treatment Option

Role of Radioiodine Treatment in DTC

DTC: Histological Subtypes and Tumor Differentiation

Differentiated Thyroid Cancer: Increasing Incidence

Latest Updated Articles

Trending on OncLive

Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC

FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC

Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC